July 6, 2017 / 11:46 AM / in 19 days

BRIEF-Bristol-Myers Squibb's Orencia receives FDA approval

1 Min Read

July 6 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb's Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis (PSA) in adults

* Bristol-Myers Squibb Co - Orencia is approved and available in both intravenous and subcutaneous injection formulations Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below